The present invention relates to new substituted quinoline compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula:
SUBSTITUTED QUINOLINE DERIVATIVES AS MITOTIC KINESIN INHIBITORS
申请人:Novartis Vaccines and Diagnostics, Inc.
公开号:EP1753723B1
公开(公告)日:2008-08-13
US7452996B2
申请人:——
公开号:US7452996B2
公开(公告)日:2008-11-18
[EN] SUBSTITUTED QUINOLINE DERIVATIVES AS MITOTIC KINESIN INHIBITORS<br/>[FR] DÉRIVÉS DE QUINOLINONE SUBSTITUÉE EN TANT QU'INHIBITEURS DE KINÉSINE MITOTIQUE
申请人:CHIRON CORP
公开号:WO2005113507A1
公开(公告)日:2005-12-01
The present invention relates to new substituted quinoline compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds as kinesin spindle protein inhibitors. The compounds of the invention have the following general formula (I).
Substituted quinoline derivatives
申请人:Wang Weibo
公开号:US20050261337A1
公开(公告)日:2005-11-24
The present invention relates to new substituted quinoline compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula: